Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

Alzheimer's disease is a progressive, clinically heterogeneous, and particularly complex
neurodegenerative disease characterized by a decline in cognition. Over the last two …

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in
2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild …

Early identification of cognitive impairment in Parkinson's disease (PD) has important clinical
and research implications. The aim of our study was to investigate the role of plasma tau …

Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-
axonal injury. The advent of highly sensitive analytical platforms that enable reliable …

Neurodegeneration is a highly complex process which is associated with a variety of
molecular mechanisms related to ageing. Among neurodegenerative disorders, Alzheimer's …

Alzheimer's disease (AD) is the most common neurodegenerative disease among the
elderly, affecting millions of people worldwide and clinically characterized by a progressive …

Immunotherapeutic efforts to slow the clinical progression of Alzheimer's disease (AD) by
lowering brain amyloid-β (Aβ) have included Aβ vaccination, intravenous immunoglobulin …

Abstract Background In Alzheimer's disease (AD), the associations between tau pathology
and brain atrophy and cognitive decline are well established, but imperfect. We investigate …

Alzheimer's disease (AD) is a rapidly growing disease that affects millions of people
worldwide, therefore there is an urgent need for its early diagnosis and treatment. A huge …